tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Biolinerx (BLRX), Steris (STE) and TRACON Pharmaceuticals (TCON)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biolinerx (BLRXResearch Report), Steris (STEResearch Report) and TRACON Pharmaceuticals (TCONResearch Report) with bullish sentiments.

Biolinerx (BLRX)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Biolinerx today and set a price target of $19.00. The company’s shares closed last Wednesday at $1.06, close to its 52-week low of $1.05.

According to TipRanks.com, Pantginis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -33.5% and a 12.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.

Biolinerx has an analyst consensus of Moderate Buy, with a price target consensus of $19.00.

See the top stocks recommended by analysts >>

Steris (STE)

In a report released today, Michael Matson from Needham maintained a Buy rating on Steris, with a price target of $263.00. The company’s shares closed last Wednesday at $212.57.

According to TipRanks.com, Matson is a 3-star analyst with an average return of 0.7% and a 43.1% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.

Currently, the analyst consensus on Steris is a Strong Buy with an average price target of $269.33.

TRACON Pharmaceuticals (TCON)

H.C. Wainwright analyst Edward White reiterated a Buy rating on TRACON Pharmaceuticals today and set a price target of $12.00. The company’s shares closed last Wednesday at $1.78, close to its 52-week low of $1.62.

According to TipRanks.com, White has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -29.2% and a 18.1% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics.

TRACON Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $10.40.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BLRX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed